Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Japan College of Rheumatology to Collaborate with Pfizer on PMS, Warns that Non-RA Specialists More Inclined to Prescribe Xeljanz
May 31, 2013
- Researcher Wearing Two Hats Should Disclose Affiliation with Greater Interests in Trials: Japan Hypertension Society
May 30, 2013
- JAMS Recognizes Violation of COI Reporting Rules over Diovan Papers
May 28, 2013
- Nat’l University Hospitals Sharing Information of Drug Purchase Prices through Central Database
May 7, 2013
- JAMS Greatly Concerned Over Diovan Paper Retractions: President Takaku
April 25, 2013
- Stivarga May Become Third/Forth-Line Colon Cancer Therapy in Japan: Prof. Sugihara
April 25, 2013
- RA Treatment Guidelines to Reflect Patients’ Values and Economic Considerations as Well as Evidence
April 24, 2013
- Osaka University Hospital to Initiate PET Microdose Study This Fall: Prof. Tomono
April 23, 2013
- New COPD Guidelines Recommend LAMA, LABA on Equal Footing
April 23, 2013
- Japan College of Rheumatology Airs Concerns over Safety of Xeljanz
April 11, 2013
- Kyoto Heart Study Chief Investigator Resigns after Diovan Paper Retractions
March 1, 2013
- Diovan Paper Contained “Careless Errors,” but “No Impact on Findings”: Chief Investigator Comments on Retraction
February 7, 2013
- JSGM Calls for 80% Generic Share, 30% Reduction in NHI Prices of Long-Listed Drugs by End of FY2017
December 6, 2012
- Less than 20% of IRBs Utilize Central IRB Despite Revised GCP Ordinance: Dr Narumoto of Okayama Univ.
December 5, 2012
- Need for Corporate Seminars May Depend on “Doctors’ Abilities”: NIRS Senior Researcher Kurihara
November 30, 2012
- AASD Scientific Meeting Shines Light on SGLT-2 Inhibitors as Next Generation Diabetes Treatment
November 28, 2012
- New Hoshi General Hospital to Give Patients Option of In-House or Legal Prescriptions Starting in January
November 22, 2012
- J-ADNI2 to Go Forward in Search of New Treatment for AD: Prof. Iwatsubo of Univ. of Tokyo
November 19, 2012
- New COPD GLs to Recommend LAMA, LABA Equally: Prof. Nagai of Tokyo Women’s Medical University
October 22, 2012
- Biosimilars Should Be Mentioned in Government Roadmap: JSGM President Muto
October 18, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…